Clarivate (CLVT) Oppenheimer 27th Virtual Annual Technology, Internet & Communications Conference summary

Financial performance and guidance

• Organic growth for the year is expected at the lower end of the initial range, with subscription growth just under 2% due to macro pressures, especially in life sciences and IP segments.

• Recurring revenues, mainly from patent and trademark renewals, are projected to be flat due to a delayed USPTO contract, pushing some revenue into next year.

• Free cash flow is anticipated at the lower end of guidance, impacted by increased capital spending and working capital timing, but overall cash generation remains strong.

• Non-subscription revenues are expected to grow in the fourth quarter, with some collections deferred to next year.

Segment performance and product innovation

• A&G segment shows strong subscription growth above 3%, driven by investments in Web of Science and high renewal rates.

• IP and life sciences segments face slight subscription declines due to product challenges and macro headwinds, but investments in new applications and real-world data platforms are ongoing.

• New AI-powered tools, such as Research Assistant for Web of Science and enhanced search in Derwent and Cortellis, are being launched to improve user experience and drive future growth.

• Transactional business is expected to see low single-digit growth in the second half, supported by improved execution and secured deals.

Strategic outlook and capital allocation

• Focus is shifting from aggressive deleveraging to a more balanced approach, prioritizing share buybacks and selective small acquisitions over debt repayment.

• Recent acquisitions (Rowan, MotionHall, Global Q) are aimed at filling product gaps and accelerating innovation, with further opportunistic M&A possible.

• Divestiture is not a current priority; the combined business model leverages shared content, technology, and commercial channels for scale and synergy.